HC Wainwright & Co. Maintains Buy on Lineage Cell Therapeutics, Maintains $9 Price Target

Benzinga · 11/24/2025 17:20
HC Wainwright & Co. analyst Joseph Pantginis maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $9 price target.